SCHEMBL5455679

SCHEMBL5455679

Cc1cccc2cc3cccc(C(=O)n4ccnc4)c3nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.41
ALDH1A1 P00352 3/20 0.41
PIK3CD O00329 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
KDM4E B2RXH2 2/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
CLK1 P49759 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RECQL P46063 1/20 0.36
TBXAS1 P24557 1/20 0.36
ELANE P08246 1/20 0.36
USP2 O75604 1/20 0.35
HTT P42858 1/20 0.35
PFKFB3 Q16875 1/20 0.35
ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458012 0.85 MAPT (0.42) LMNAALDH1A1KMT2AMEN1KDM4E
SCHEMBL5462961 0.83 HDAC1 (0.41) LMNAALDH1A1HPGDTBXAS1
SCHEMBL2011181 0.79 LMNA (0.53) LMNAALDH1A1KMT2AMEN1KDM4E
SCHEMBL15763697 0.79 ELANE (0.55) LMNAALDH1A1KMT2AMEN1HPGD
SCHEMBL5459806 0.74 ALDH1A1 (0.50) LMNAALDH1A1KMT2AKDM4EPOLB
SCHEMBL30366356 0.74 FAAH (0.44) LMNAALDH1A1KDM4ETBXAS1ELANE
SCHEMBL10118094 0.74 ALDH1A1 (0.54) LMNAALDH1A1KMT2AKDM4EPOLB
SCHEMBL5448082 0.73 PARP1 (0.48) LMNAALDH1A1KDM4ETBXAS1
SCHEMBL7572956 0.73 PARP1 (0.61) ALDH1A1KDM4E
SCHEMBL5449147 0.73 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2007-08-16 US disclosed
WO-2004026846-A1 DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2004-04-01 WO disclosed
EP-1173414-A1 N-PROTECTED AMINES AND THEIR USE AS PRODRUGS CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2002-01-23 EP disclosed
WO-2000064864-A9 N-PROTECTED AMINES AND THEIR USE AS PRODRUGS CANCER RES CAMPAIGN TECH (GB) 2001-12-27 WO disclosed
WO-2000064864-A1 N-PROTECTED AMINES AND THEIR USE AS PRODRUGS CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy HIF1AN, HIF1A, HYOU1 LMNA 1858/4885ALDH1A1 709/4885PIK3CD 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.